Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Biotechnology

Healthcare
$95.05 +0.77%

+$0.42 today

Market cap
$7.47B
Beta
0.12
P/E (TTM)
57.2
EPS (TTM)
$0.95
52W Low $26.27High $59.87

Volume 0.33M

Average 0.66M

KNSA Income Before Tax

Profit after all operating and non-operating items but before income tax.

Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax grows, but more slowly than its trailing trend

Q2 FY2026 income before tax of $31.15M rose 36.1% year over year, behind the +701.1% change in trailing-twelve-month income before tax. Sequentially, it fell 4.7% from the prior quarter. Over 3 fiscal years it compounded at +100.5% a year.

Context

  • Income before tax amounted to 13.1% of revenue in FY2025, up 4.6 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +36.1% toward the trailing-twelve-month pace of +701.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$31.15M-4.7% QoQ
Last fiscal yearDec 2025
$88.87M+345.8% YoY
LTMJun 2026
$114.25M+701.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+36.1%——
1 year+345.8%——
3-year CAGR+100.5%——
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
88.87M USD
Year-over-year change
+345.8%

Income Before Tax vs competitors

How KNSA compares with its peers on the latest reported figures

  • KNSA's LTM Jun 2026 income before tax of $114.25M is the 2nd highest of the 10 companies compared; the peer median is -$69.66M.
  • Its year-over-year change of +701.1% is the highest of 10, against a peer median of +46.5%.
  • Income before tax amounts to 13.6% of revenue for KNSA, versus a peer median of 562.1%.
KNSA Competitors Peer median
Income Before Tax for KNSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$308.21M +226.3%—43.9%
KNSAKiniksa Pharmaceuticals, Ltd.LTM Jun 2026$114.25M +701.1%+100.5%13.6%
PHARPharming Group N.V.LTM Mar 2026$19.88M +643.8%-4.9%5.4%
ANABAnaptysBio, Inc.LTM Mar 2026-$26.63M +81.1%—11.5%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-$29.91M +73.9%—1570.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M +46.5%—832.6%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026-$84.57M -215.6%—143340.7%
ORKAOruka Therapeutics, Inc.LTM Sep 2026-$152.57M -39.7%——
SYRESpyre Therapeutics, Inc.LTM Sep 2026-$263.86M -77.1%—291.6%
IMVTImmunovant, Inc.LTM Sep 2026-$510.25M -10.3%—7191.7%
Peer median (excluding KNSA) -$69.66M+46.5%-4.9%562.1%

Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.54M220.18M270.26M423.24M677.56M
Cost of Revenue9.1M22.9M56.52M60.91M307.41M
Gross Profit29.44M197.29M213.74M362.33M370.15M
Gross Margin76.4%89.6%79.1%85.6%54.6%
Research & Development99.3M65.49M76.1M111.62M96.85M
Selling, General & Admin85.95M97.95M129.43M168.01M196.27M
Operating Expenses186.08M187.51M238.93M407.95M292.93M
Depreciation & Amortization2.36M2.4M2.34M1.7M1.55M
EBITDA(154.18M)13.43M(14.31M)(34.46M)90.42M
EBITDA Margin-400.0%6.1%-5.3%-8.1%13.3%
Operating Income(156.64M)9.77M(25.2M)(45.62M)77.22M
Operating Margin-406.4%4.4%-9.3%-10.8%11.4%
Interest Income97K1.25M8.54M9.46M11.65M
Interest Expense00000
Other Income / Expenses97K1.25M8.54M9.46M11.65M
Income Before Tax(156.54M)11.03M(16.65M)(36.15M)88.87M
Pre-Tax Margin-406.1%5.0%-6.2%-8.5%13.1%
Income Tax Expense1.39M(172.34M)(30.74M)7.04M29.86M
Net Income(157.92M)183.36M14.08M(43.19M)59.01M
Net Margin-409.7%83.3%5.2%-10.2%8.7%
EPS (Basic)(2.30)2.640.20(0.60)0.80
EPS (Diluted)(2.30)2.600.20(0.60)0.75
Weighted Avg Shares68.58M69.38M70.06M71.42M74.2M
Weighted Avg Shares (Diluted)68.58M70.42M71.92M71.42M78.98M

Kiniksa Pharmaceuticals, Ltd.

NASDAQ:KNSA

Intrinsic Alpha fair value

Locked

Current Price

$95.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.